ACE and kidney disorder: Although only a few clinical trials have formally tested a head to head comparison between ACE-Is and ARBs, based on the results of several small studies and one reasonably large trial (comparing telmisartan and enalapril in patients with type 2 diabetes and incipient renal disease) [35], ACE-Is and ARBs have traditionally been assumed to provide comparable renal protection, in the context of undisputed superior tolerability of the latter.